# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The FTC is investigating Teva Pharmaceuticals for alleged misuse of inhaler patents to block generic competition and maintain h...
https://www.washingtonpost.com/health/2024/07/01/teva-patent-pharma-generic-inhaler/The Federal Trade Commission has opened an ...
4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) co...
Jefferies analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target fro...
This allows Teva to end this historical income tax issue, and to continue to focus on its commitment to the health of patients ...